Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

Abstract Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44‐targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and...

Full description

Bibliographic Details
Main Authors: Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz‐Riascos, Alejandro Sánchez‐Chardi, Marie‐Eve Beaulieu, Joaquin Seras‐Franzoso, Laura Sánchez‐García, Ricardo Baltà‐Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz Jr, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther Vázquez
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Advanced Science
Subjects:
biofabrication
cancer therapy
functional amyloids
inclusion bodies
protein drug release
Online Access:https://doi.org/10.1002/advs.201900849
Description
Summary:Abstract Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44‐targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.
ISSN:2198-3844

Similar Items